General Session 1
Zusammenfassungen erscheinen bald
- GS01-01 Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL
- GS01-02 Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756
- GS01-03 Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
- GS01-05 Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
- GS01-06 Advancing Evidence of the Associations Between Specific Benign Breast Diagnoses and Future Breast Cancer RIsk
- GS01-08 CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer
- GS01-10 HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
Sherene Loi, Giuseppe Curigliano, Roberto Salgado, et al.
GS01-01 Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL
Zusammenfassung folgt
Fatima Cardoso, Joyce O'Shaughnessy, Heather McArthur, et al.
GS01-02 Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756
Zusammenfassung folgt
Michail Ignatiadis, Andrew Bailey, Heather McArthur, et al.
GS01-03 Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial
Zusammenfassung folgt
Hope Rugo, Mark Robson, Seock-Ah Im, et al.
GS01-05 Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
Zusammenfassung folgt
Olivia Sattayapiwat, Karla Kerlikowske, Donald Weaver, et al. (Kopie)
GS01-06 Advancing Evidence of the Associations Between Specific Benign Breast Diagnoses and Future Breast Cancer RIsk
Zusammenfassung folgt
Ze-Yi Zheng, Anran Chen, Eric Jaehnig, et al.
GS01-08 CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer
Zusammenfassung folgt
Sara Hurvitz, Sherene Loi, Joyce O'Shaughnessy, et al.
GS01-10 HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer
Zusammenfassung folgt